ArticleRSC advances2022
Graph-sequence attention and transformer for predicting drug-target affinity.
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Graph-based drug-target interaction modeling: from representation learning to output-driven drug discovery.Briefings in bioinformatics · 2026Review
- Graph Learning in Bioinformatics: A Survey of Graph Neural Network Architectures, Biological Graph Construction and Bioinformatics Applications.Biomolecules · 2026Review
- Predicting blood-brain barrier permeability of molecules with a large language model and machine learning.Scientific reports · 2024Article
- Machine Learning Empowering Drug Discovery: Applications, Opportunities and Challenges.Molecules (Basel, Switzerland) · 2024Review
- DLM-DTI: a dual language model for the prediction of drug-target interaction with hint-based learning.Journal of cheminformatics · 2024Article
- Attention is all you need: utilizing attention in AI-enabled drug discovery.Briefings in bioinformatics · 2023Review
- Multi-task bioassay pre-training for protein-ligand binding affinity prediction.Briefings in bioinformatics · 2023Article
- Tutorial: a guide for the selection of fast and accurate computational tools for the prediction of intrinsic disorder in proteins.Nature protocols · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-target binding affinity (DTA) prediction has drawn increasing interest due to its substantial position in the drug discovery process. The development of new drugs is costly, time-consuming, and often accompanied by safety issues. Drug repurposing can avoid the expensive and lengthy process of drug development by finding new uses for already approved drugs. Therefore, it is of great significance to develop effective computational methods to predict DTAs. The attention mechanisms allow the computational method to focus on the most relevant parts of the input and have been proven to be useful for various tasks. In this study, we proposed a novel model based on self-attention, called GSATDTA, to predict the binding affinity between drugs and targets. For the representation of drugs, we use Bi-directional Gated Recurrent Units (BiGRU) to extract the SMILES representation from SMILES sequences, and graph neural networks to extract the graph representation of the molecular graphs. Then we utilize an attention mechanism to fuse the two representations of the drug. For the target/protein, we utilized an efficient transformer to learn the representation of the protein, which can capture the long-distance relationships in the sequence of amino acids. We conduct extensive experiments to compare our model with state-of-the-art models. Experimental results show that our model outperforms the current state-of-the-art methods on two independent datasets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.